Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose-escalation Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Parenteral Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6.

NCT04752215 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04752215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose-escalation Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Parenteral Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
May 18, 2021
Completion date
December 17, 2024
Enrollment
67 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, carcinoma, non-small-cell lung, pancreatic neoplasms, carcinoma, hepatocellular, head and neck neoplasms, gastrointestinal neoplasms